Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | EED | O75530 | 3/20 | 0.34 |
| ▸ | RBBP4 | Q09028 | 3/20 | 0.34 |
| ▸ | SUZ12 | Q15022 | 3/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.34 |
| ▸ | AEBP2 | Q6ZN18 | 3/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12535993 | 0.87 | PIK3CA (0.49) | PIK3CAPIK3C3MAP3K14DYRK1A | |
| SCHEMBL989559 | 0.86 | PIK3CA (0.60) | PIK3CAADORA2AADORA1EEDRBBP4 | |
| SCHEMBL989307 | 0.85 | PIK3CA (0.56) | PIK3CAPIK3C3MAP3K14 | |
| SCHEMBL12535994 | 0.84 | PIK3CA (0.47) | PIK3CAPIK3C3MAP3K14DYRK1A | |
| SCHEMBL12750177 | 0.82 | PIK3CA (0.66) | PIK3CAPIK3C3MAP3K14DYRK1A | |
| SCHEMBL988621 | 0.76 | PIK3CA (0.47) | PIK3CAEEDRBBP4SUZ12EZH2 | |
| SCHEMBL989293 | 0.76 | PIK3CA (0.66) | PIK3CAEEDRBBP4SUZ12EZH2 | |
| SCHEMBL1043434 | 0.74 | PIK3CA (0.63) | PIK3CAPIK3C3MAP3K14 | |
| SCHEMBL989263 | 0.74 | PIK3CA (0.62) | PIK3CAPIK3C3MAP3K14 | |
| SCHEMBL989545 | 0.72 | PIK3CA (0.60) | PIK3CAPIK3C3MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309265-B2 | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140336154-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN-LA ROCHE INC. | 2014-11-13 | — | — | US | disclosed |
| US-8846762-B2 | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2276767-B1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20130123263-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN - LA ROCHE AG (CH) | 2013-05-16 | — | — | US | disclosed |
| US-8399690-B2 | 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulene compounds | GENENTECH, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110130363-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7928248-B2 | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| WO-2009123971-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090247567-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336154-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | PIK3CA 1/4885ADORA2A 4392/4885ADORA1 4306/4885 |
| US-20110130363-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | PIK3CA 1/4885ADORA2A 4392/4885ADORA1 4306/4885 |
| US-20090247567-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | PIK3CA 1/4885ADORA2A 4392/4885ADORA1 4306/4885 |
| US-20130123263-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | PIK3CA 1/4885ADORA2A 4517/4885ADORA1 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.